Aims To prospectively evaluate the influence of stent length on 6 month clinical and angiographic outcome, in patients with native coronary lesions up to 45 mm in length, undergoing elective Magic Wallstent implantation.
Introduction
In 1986 the self-expanding Wallstent was the first stent to be implanted in human coronary arteries to treat acute vessel closure and late restenosis after angioplasty [1] . Over the past decade, it has been widely used in clinical practice, particularly for longer lesions and diseased bypass grafts [2] [3] [4] . A previous multicentre observational study with the second-generation 'lessshortening' Wallstent described favourable clinical and angiographic outcomes in a high-risk patient group, but showed that longer stents were associated with greater restenosis [5] . Since that study was not designed to evaluate the influence of stent length on outcome, the Magic 5L study was conceived to prospectively investigate the relationship between Wallstent length and late clinical and angiographic results. The safety and efficacy of the design could also be documented.
Methods
The Magic Wallstent is a third generation stent, with a lowered profile (6 French compatible), higher radioopacity and an improved delivery system, to allow recapturing during deployment. It is available in five lengths, for lesions from 5-45 mm, and in four diameter derivations for vessels from 3·0-5·0 mm. The study was a prospective international multicentre registry using a unique design, whereby each of the five available stent lengths would be implanted in a minimum of 50 patients.
Eligible patients scheduled for percutaneous coronary intervention were assigned to the intended stent length on the basis of the pre-procedural angiogram. The study was centrally coordinated by an independent clinical coordinating centre and angiographic core laboratory (Cardialysis, Rotterdam, The Netherlands). Clinical follow-up was done at 1, 6 and 9 months after the procedure. Late restenosis was assessed at the 6 month angiography follow-up.
Exclusion criteria
Exclusion criteria included: intolerance or contraindication to acetyl salicylic acid and/or ticlopidine, leukopenia, neutropenia, thrombocytopenia, peptic ulcer or upper gastrointestinal bleeding in the previous 6 months; acute myocardial infarction within 1 week prior to intervention, documented previous Q wave infarction in the territory supplied by the vessel to be stented and a large akinesia in this territory, an ejection fraction below 30%, cardiogenic shock, left bundle branch block or bifascicular block, severe hepatic disease; intended stenting of a left main coronary artery lesion, lesion at an important bifurcation, angiographic evidence of thrombus, or heavily calcified lesions, where full expansion of the pre-dilatation balloon could not be achieved.
End-points Primary end-points
The primary clinical end-point for the efficacy and comparative analysis was the cumulative incidence of major adverse cardiac events at the 6 month follow-up, as defined previously [6] . The primary angiographic endpoint was late restenosis outcome at 6 months, measured by off-line quantitative coronary angiography. Parameters to assess restenosis were minimal luminal diameter, diameter stenosis, categorical restenosis (defined as a diameter stenosis greater than 50%), late loss and loss index (late loss/acute gain).
Secondary end-points
The safety of Magic Wallstent implantation was evaluated on the basis of clinical status at 30 days post-procedure, including major adverse cardiac events, bleeding complications and subacute stent occlusion.
Stent implantation and angiographic procedure
There were five Wallstent length categories: mini, extra-short, short, medium and long and four diameter categories, 3·5, 4·0, 4·5 and 5·0; this diameter refers to the diameter the stent would achieve when completely expanded. Each unit carries a recommendation on the packing for vessel diameter and a length/diameter chart for reference. After adequate pre-dilatation, it was recommended to choose a Wallstent 0·5-1·0 mm larger than the maximal target reference diameter. In addition, the length chosen was recommended to be 4-8 mm longer than the lesion, to allow adequate anchoring of the stent proximal and distal, with the intention of covering the lesion with a single Magic Wallstent. Postdilatation was recommended to achieve optimal stent expansion (diameter stenosis <20% by online quantitative coronary angiography in the worst angiographic view). If the lesion was not completely covered by the chosen Magic Wallstent, or if there was a significant edge dissection, a second Magic Wallstent could be implanted. Use of other stents was discouraged. Coronary angiography was documented in at least two views after intracoronary injection of 0·1-0·3 mg nitroglycerin or 1-3 mg isosorbide dinitrate, at baseline and repeated post-procedure, after removal of the guidewire. Standardized procedures were followed to facilitate quantitative analysis at the core laboratory, as has been extensively described in the past [5] [6] [7] [8] [9] [10] . Intravascular ultrasound was permitted according to operator's usual clinical practice.
Medication
All patients were pre-treated with aspirin 80-325 mg per day continuing indefinitely, ticlopidine (beginning preprocedure with 1 g and continuing with 500 mg per day for a minimum of 2 weeks) and heparin bolus according to local practice, to maintain activated clotting time during the procedure >300 s. Platelet GP IIb/IIIa antagonists could be used before, during or after stenting, with documentation of timing and indication. Other medications were at the discretion of the treating physician.
Statistical analysis
Magic 5L is an observational, non-randomized clinical trial. Descriptive statistics were used. Continuous variables are presented as means with their 95% confidence interval, whenever appropriate, or as median and range. Categorical variables are presented as a rate with its 95% confidence interval. Analysis of variance was used to compare continuous outcome variables among the groups. Comparison of categorical variables was by chi-square test, dividing stent length into short (mini, extra-short and short) and long (medium and long). Logistic and linear multivariate regression techniques were used to investigate the independent influence of stent length on angiographic and clinical outcome. The analysis of clinical end-points was carried out with patients as units of measurement, analysis of angiographic end-points was carried out with the 'stented segment' as the unit of measurement, among patients treated with a single Magic Wallstent per lesion and with analysable angiograms at baseline and at 6 months. If a revascularization procedure involving the stented lesion was performed before the appointed time for the 6 month angiogram, the pre-procedural angiogram was used for angiographic end-point evaluation.
Results

Between 17 September 1997 and 23 October 1998, 15
European sites enrolled 276 patients with a total of 302 lesions, in 301 of which a Magic Wallstent was successfully implanted. Baseline demographic and lesion characteristics are listed in Fig. 1 and Table 1 , respectively. The distribution of the different stent lengths used was 33 mini, 62 extra-short, 72 short, 52 medium and 45 long Magic Wallstents. (The study was curtailed at this time, as it appeared unlikely to reach 50 patients in the mini group within a reasonable time frame.) A total of 38 lesions were treated with an additional stent (12·6%) of which eight were non-Magic Wallstents. An optimal angiographic result was achieved in 98·6% of lesions.
In-hospital major adverse cardiac events occurred in seven patients: two patients (0·7%) Q-wave myocardial infarction, three patients (1%) non-Q wave myocardial infarction and two patients (0·7%) re-PTCA. Mean hospital stay was 1·9 3·4 days. Dissections postprocedure were noted in 36 patients (12·1%), approximately half of which (5·7%) were located within the stent.
Primary end-points
Overall clinical outcome At 6 months follow-up, 76 patients (27·5%) had experienced major adverse cardiac events, of which five were fatal (1·8%). One patient died from previously undiagnosed prostate malignancy and four deaths were cardiac. Twelve patients (4·3%) experienced myocardial infarction of whom seven (2·5%) had a Q-wave and five (1·8%) a non-Q wave myocardial infarction. Five (1·8%) patients underwent CABG and 54 (19·6%) had re-PTCA for significant in-stent restenosis. At the 9 month followup, an additional eight patients (2·9%) had major adverse cardiac events, of whom two had undergone CABG and six re-PTCA, yielding 69·6% event-free survival.
Overall angiographic outcome
Serial matched quantitative coronary angiography data were complete in 83% of the patients (Table 2) . Vessel size varied among five lesion groups; on average it was 3·01 mm, minimal luminal diameter post-procedure was 2·61 0·37 mm, acute gain was 1·67 mm, with a residual 
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diameter stenosis of 17·9%. At the 6-month follow-up, the minimal luminal diameter was 1·60 0·73 mm with a mean diameter stenosis of 45·9%, a restenosis rate of 37% and a mean loss index of 0·64.
Outcome comparisons between the five groups
For valid inter-group comparisons, patients with more than one lesion treated and those with more than a single Magic Wallstent were excluded. Tables 3 and 4 and Fig. 1 show angiographic and clinical outcome data among the five patient groups. Variations in vessel size are appreciated. It is also worth mentioning that the restenosis rate was similar for the three shorter stent groups, being lowest in the short stent group, so that up to a mean stent length of 20 mm, no significant change in restenosis rate was observed. Making a categorical distinction between shorter (mini, extra-short and short) and longer stents (medium and long), it is apparent that the post-procedural result was superior in the shorter stent groups, 16% vs 20% diameter stenosis. At followup, all outcome parameters were superior in the shorter stent groups: % diameter stenosis, minimal luminal diameter at follow-up, restenosis rate, late lumen loss, loss index, as well as the cumulative frequency of major adverse cardiac events (Fig. 2) , particularly target lesion revascularization (23·8% vs 33·7%, P=0·048). Multivariate analyses were performed, including all known clinical procedural and angiographic variables known or thought to have an influence on the occurrence of major adverse cardiac events or on angiographic restenosis or minimal luminal diameter at follow-up (including stent length and multiple and overlapping stents). Stent length was the only variable to be retained in each of the three models, being significantly independently predictive of a smaller minimal luminal diameter at follow-up (P=0·0001) and a higher incidence of angiographic restenosis (P=0·0001) and major adverse cardiac events (P=0·0001). A larger postprocedural diameter (P=0·0001), age (P=0·008) and prior PTCA (P=0·03) were predictors of a larger minimal luminal diameter at follow-up and a larger postprocedural minimal luminal diameter was also predictive of a lower restenosis rate (P=0·002).
Secondary end-points
Safety, acute/subacute occlusion, bleeding complications Safety evaluation was at 30 days, by which time 6·2% of patients had experienced major adverse cardiac events, with one death (0·4%), nine myocardial infarctions (four Q and five non-Q) (3·3%), one CABG (0·4%) and six re-PTCAs (2·2%). Acute occlusion occurred in one patient due to vessel perforation, with emergency CABG and death on day 8 due to cerebrovascular accident. Subacute occlusion occurred pre-discharge in four patients (1·4%) and in another patient 5 days post-discharge. In three cases the occlusion could be successfully treated by re-PTCA and in one myocardial infarction occurred followed 3 days later by CABG. Two patients experienced major bleeding (0·7%) in the interval between discharge and 30-day follow-up.
Discussion
Long lesions are known to be associated with higher restenosis rates after balloon angioplasty [9, 10] , and use of adjunctive devices such as Rotablator [11] and excimer laser [12] , although initially facilitating acute success, did not lead to improvement in late outcome. Stent implantation is now widely practised for all lesion subsets, although strictly speaking, only of proven benefit for short lesions, proximal left anterior descending coronary artery lesions, chronic total occlusions and saphenous vein graft lesions [7, [13] [14] [15] [16] . Empirical use of stenting for long lesions is, at this time, not supported by published results from a randomized clinical trial. In this study we sought to evaluate the influence of stent length on late clinical and angiographic outcome using the Magic Wallstent, which was available in a range of lengths suitable for revascularization of lesions from 5-45 mm in length. Although implantation was safe and acutely effective in the short term in this comparatively high risk 
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heterogeneous patient group, elective implantation of medium and long Magic Wallstents was associated with unacceptably high angiographic restenosis and an increased frequency of major adverse cardiac events and for this reason cannot be recommended. Implantation of multiple stents per lesion was not found to be associated with adverse outcome, presumably because the stent length parameter was such a strong predictor and also since multiple stents were only required in 12% of patients, mainly in the shorter stent groups. The overall event-free survival rate at the 6 month follow-up of 72·5% is comparable with the data from the Wellstent native study (75·2%) [5] , but somewhat lower than published results of trials using balloon expandable stents, such as BENESTENT [7] and STRESS [13] . These studies restricted inclusion to stable patients with short lesions in larger vessels, whereas Magic 5L included a heterogeneous group of patients with a high prevalence of unstable angina and considerably longer lesions. The angiographic and clinical outcomes among patients receiving shorter Magic Wallstents in this study compare favourably with BENESTENT and STRESS trials, even though the mean stent length in this study is actually somewhat longer (Table 3) . Thus, it must be concluded that the Magic Wallstent itself is inherently an adequate device for elective coronary revascularization, but implantation of longer stents is associated with poorer results.
Previous large retrospective studies in single centres have described similarly disappointing results with elective stenting of long lesions [17] and lesion length has been identified as an independent risk factor for in-stent restenosis and adverse cardiac events [18] . The ADVANCE trial was initiated to specifically address the issue of the additional value of stenting long lesions after achieving a satisfactory balloon angioplasty result (defined as diameter stenosis <30% by on-line quantitative coronary angiography). After 34% of lesions had required 'bail-out' stenting, because of unacceptable or occlusive dissection or diameter stenosis >50%, despite repeat inflations, the remaining patients were randomly assigned to additional stenting or acceptance of the result. Interim analysis revealed inferior clinical results at 6 months in the additional stenting group, whereas the power calculation for the study had been based on an assumption of a 30% reduction in major adverse cardiac events by stenting [19] . Accordingly, the study was terminated with the conclusion that a strategy of 'provisional stenting' [20] was appropriate for percutaneous revascularization of long lesions.
Since all of these studies have employed a variety of stent types, it seems that the adverse outcomes are independent of the stent design, although the Wallstent has historically tended to be linked with poorer outcomes, without objective evidence to prove this. Escaned et al. [21] , investigated the influence of stent design on late outcome and reported a higher loss index for the self-expanding Wallstent (0·60 0·41) compared to multicellular (0·27 0·26) and slotted tube (0·33 0·40) stent designs. However, the length of the stented segment (a predictor of restenosis in that study also) was significantly higher in the self-expanding stent group. The loss index in the Magic 5L study was 0·64 0·44 increasing with increasing stent lengths (from 0·50 0·44 for the mini -similar to that reported by Kuntz et al. for all coronary devices [22] -up to 0·77 0·33 for the long Magic Wallstent). Even though the loss index for the mini, extra-short and short stents is higher than that of the slotted tube and multicellular stents reported by Escaned et al. [21] , this does not in fact translate into higher restenosis rates. As an explanation of greater intimal hyperplasia associated with Wallstent use, strut overlap and chronic outward expansion were proposed by Von Birgelen et al. [23] , in a three dimensional intravascular ultrasound study; however, inherently longer stent length was overlooked. Thus it seems likely that the adverse results until now associated with the Wallstent may be a consequence of the fact that the stent length being used was significantly longer than the average length of balloon-expandable stents used in comparative studies and clinical practice.
Clinical implications and future directions
For practical purposes, it would be useful to define a cut-off point for lesion length beyond which the results of stenting become unacceptable. As there is in fact a continuous relationship between stented segment length and late restenosis (Fig. 3) , there is no practically applicable cut-off point and since multiple other factors including vessel diameter, lesion location, anginal status, diabetic status and extent of vessel disease also play important determining roles [8] [9] [10] 18, 21, 22] individual cases need to be judged as such and the combination of risk factors taken into account when deciding on alternative therapies. The place of so-called 'spot stenting' and of a policy of 'provisional stenting' in long lesions [20] , as well as new rotablation techniques [24] needs to be objectively evaluated. Furthermore, the optimal methods of judging and guiding acute outcome (i.e. the place of fractional flow reserve, coronary flow reserve and intravascular ultrasound) need to be established. New adjunctive therapies, which may reduce restenosis and improve late clinical outcome, need to be urgently evaluated in this highrisk lesion subset. For example, if stent coating with antiproliferative compounds, such as rapamycin [25] , or catheter-based brachytherapy [26] can reduce restenosis after stenting of long lesions into the range of 'short' lesions, then perhaps elective stenting of long lesions would be an acceptable therapy.
Limitations
This was a non-randomized clinical trial and therefore lacks a 'conventional' control group. A direct comparison with balloon angioplasty in long coronary lesions may have been more objective, but the purpose was to comparatively evaluate Magic Wallstent results in short and long lesions, since shorter Wallstents had not previously been critically evaluated. It was intended to recruit 50 patients per group, but after the ordained study period, there was insufficient in the mini group and the sponsor requested closing the study after 276 patients had been recruited. It would have been ideal to 
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have limited inclusion to a single lesion per patient so as to couple clinical and angiographic outcomes with stent length category, but investigators believed recruitment would be too low if multilesion intervention was not allowed. As is usual for Wallstent studies, target lesion distribution shows a higher prevalence of the right coronary artery lesions, compared to traditional interventional studies and daily clinical practice. Since left anterior descending coronary artery location has a higher restenosis propensity [8, 22] , this imbalance could produce more favourable results compared with other trials, although left anterior descending coronary artery location itself was not an independent predictor of poor outcome in this study.
Conclusions
This was the first prospective multicentre study to compare different lengths of the same stent type in order to assess the influence of stent length on clinical and angiographic outcomes. The safety and feasibility of the Magic Wallstent was excellent. While the shorter versions of the Magic Wallstent proved to be equipotent tools with balloon-expandable stents, longer stents were shown to be associated with significantly increased restenosis and clinical events (mainly target lesion revascularization). Elective stenting of long coronary lesions thus appears ill advised and while optimal therapy remains to be established, there is a necessity for urgent evaluation of promising adjunctive therapies such as stent coatings and catheter-based brachytherapy.
